| Ytd | -6.64% | |
| 1y | -26.23% |
| Open | 4.24 | Prev Close | 4.26 | Low | 4.23 | High | 4.38 | Mkt Cap | 96.26M |
| Vol | 0.00 | Avg Vol | 724.34K | EPS | -8.57 | P/E | -0.51 | Forward P/E | -0.89 |
| Beta | 0.87 | Short Ratio | 5.53 | Inst. Own | 79.11% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 4.41 | 200-d Avg | 3.48 | 1yr Est | 29.71 |
ADVM News
Adverum Biotechnologies, Inc. (NASDAQ: ADVM - Get Free Report) has been given a consensus recommenda
Stock News Fed set for a âhawkish cutâ: The Federal Reserve is widely expected to deliver a thir
INDIANAPOLIS , Dec. 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Adverum Biotechno
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM)
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
Adverum Biotechnologies (NASDAQ: ADVM - Get Free Report) is expected to be issuing its Q3 2025 resul
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
NEW YORK , Oct. 24, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass
MILWAUKEE , Oct. 24, 2025 /PRNewswire/ -- The Ademi Firm is investigating Adverum (Nasdaq: ADVM) for
Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal v
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is invest
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated
Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously
REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM
- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and p
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM)
REDWOOD CITY, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM)
- Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatm
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP is investigating claims on behalf of i
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.